4-O-deacetyl vinorelbine: active metabolite of vinorelbine
ID Source | ID |
---|---|
PubMed CID | 21783126 |
CHEMBL ID | 537777 |
MeSH ID | M0510816 |
Synonym |
---|
CHEMBL537777 |
xkd4u87szy , |
o-deacetylnavelbine |
unii-xkd4u87szy, xkd4u87szy, 4-o-deacetylvinorelbine |
DTXSID10925513 |
4-o-deacetyl vinorelbine |
vinorelbine tartrate impurity b [ep impurity] |
aspidospermidine-3-carboxylic acid, 6,7-didehydro-15-((2r,6r,8s)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2h-azecino(4,3-b)indol-8-yl)-3,4-dihydroxy-16-methoxy-1-methyl-, methyl ester, (2.beta.,3.beta.,4.beta.,5.alpha.,12r,19.alpha.)- |
o4-deacetyl-4-deoxy-3,4-didehydro-8-norvincaleukoblastine |
4-o-deacetylvinorelbine |
Excerpt | Relevance | Reference |
---|---|---|
" Drug concentrations at high nanomolar levels and above, which are relevant to conventional pulsatile dosing of VRL, induced a dose-dependent and nuclear factor-κB-related increase in proangiogenic interleukin-8 and cyclooxygenase-2 and a decrease in the thrombospondin-1 receptor CD36 and peroxisome proliferator-activated receptor γ at mRNA and protein levels." | ( Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells. Biziota, E; Briasoulis, E; Harris, AL; Marselos, M; Mavroeidis, L; Pappas, P, 2016) | 0.43 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.78) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |